Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Journal of Psychopharmacology

Volumn 25, Issue 11, 2011, Pages 1453-1461

  MacLean, Katherine A ^a   Johnson, Matthew W ^a   Griffiths, Roland R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hallucinogen; mystical experience; openness; personality; psilocybin; psychedelic

Indexed keywords

PSILOCYBINE;

ADULT; AGREEABLENESS; ARTICLE; CONSCIENTIOUSNESS; CONTROLLED STUDY; CREATIVITY; EXTRAVERSION; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMAGINATION; LIFE EVENT; MALE; MYSTICAL EXPERIENCE; NEUROSIS; NORMAL HUMAN; OPENNESS; PERSONALITY; PERSONALITY DISORDER; PRIORITY JOURNAL;

ADULT; ATTITUDE; BEHAVIOR; DOUBLE-BLIND METHOD; EXTRAVERSION (PSYCHOLOGY); FEMALE; FOLLOW-UP STUDIES; HALLUCINOGENS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYSTICISM; PERSONALITY; PSILOCYBINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 83455162410     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111420188     Document Type: Article

References (55)

1. Bouchard TJ, Lykken DT, McGue M, Segal NL, Tellegen A. Sources of human psychological differences: the Minnesota Study of Twins Reared Apart. Science. 1990 ; 250: 223-228 (Pubitemid 20354229)
2. Cloninger CR. Temperament and personality. Curr Opin Neurobiol. 1994 ; 4: 266-273 (Pubitemid 24126293)
3. Costa PT, Bagby RM, Herbst JH, McCrae RR. Personality self-reports are concurrently reliable and valid during acute depressive episodes. J Affect Disord. 2005 ; 89: 45-55 (Pubitemid 41740832)
4. Costa PT, Herbst JH, McCrae RR, Siegel IC. Personality at midlife: stability, intrinsic maturation, and response to life events. Assessment. 2000 ; 7: 365-378
5. Costa PT, McCrae RR Revised NEO Personality Inventory (NEO-PI-R) and NEO Five Factor Inventory (NEO-FFI) Professional Manual. Odessa, FL: Psychological Assessment Resources ; 1992 :
6. DeYoung CG, Peterson JB, Higgins DM. Sources of openness/intellect: cognitive and neuropsychological correlates of the fifth factor of personality. J Pers. 2005 ; 73: 825-858 (Pubitemid 40937811)
7. DeYoung CG, Shamosh NA, Green AE, Braver TS, Gray JR. Intellect as distinct from Openness: differences revealed by fMRI of working memory. J Pers Soc Psychol. 2009 ; 97: 883-892
8. Digman JM. Personality structure: emergence of the five-factor model. Annu Rev Psychol. 1990 ; 41: 417-440
9. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998 ; 31 (Suppl 2). 80-84 (Pubitemid 28396276)
10. Doblin R. Pahnke's good friday experiment: a long-term follow-up and methodological critique. J Transpers Psychol. 1991 ; 23: 1-28
11. Glennon RA, Titeler M, McKenney D. Evidence for the 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984 ; 35: 2505-2511 (Pubitemid 15212191)
12. Griffiths RR and Grob CS (2010) Hallucinogens as medicine. Scientific American December: 77-79.
13. Griffiths RR, Johnson MW, Richards WA, Richards BR, McCann UD and Jesse R (2011) Psilocybin-occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 00:00-00.
14. Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008 ; 22: 621-632
15. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006 ; 187: 268-283; discussion 284-292 (Pubitemid 44088380)
16. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011 ; 68: 71-78
17. Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 1996 ; 184: 86-94 (Pubitemid 26092979)
18. Halpern JH. The use of hallucinogens in the treatment of addiction. Addict Res. 1996 ; 4: 177-189 (Pubitemid 126464293)
19. Hood RW. The construction and preliminary validation of ameasure of reported mystical experience. J Sci Study Relig. 1975 ; 14: 29-41
20. Hood RW Mysticism: A Variety of Psychological Perspectives. Belzen JA Geels A, ed. New York: Rodopi ; 2003: 17-54.
21. Hood RW, Ghorbani N, Watson PJ, et al. Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran. J Sci Study Relig. 2001 ; 40: 691-705
22. Isbell H. Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia. 1959 ; 1: 29-38
23. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008 ; 22: 603-620
24. Kast EC. Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide. Psychiatry Q. 1967 ; 41: 646-657
25. Kelly JF, Stout RL, Magill M, Tonigan JS, Pagano M. Spirituality in recovery: a lagged mediational analysis of Alcoholics Anonymous' principle theoretical mechanism of behavior change. Alcohol Clin Exp Res. 2011 ; 35: 454-463
26. Lerner M, Lyvers M. Values and beliefs of psychedelic drug users: a cross-cultural study. J Psychoactive Drugs. 2006 ; 38: 143-147 (Pubitemid 44141293)
27. McAdams DP. What do we know when we know a person?. JPersonal. 1995 ; 63: 365-396
28. MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotimization of quantitative variables. Psychol Methods. 2002 ; 7: 19-40
29. Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs. 1998 ; 30: 381-418 (Pubitemid 29046930)
30. McCoubrie RC, Davies AN. Is there a correlation between spirituality and anxiety and depression in patients with advanced cancer?. Support Care Cancer. 2006 ; 14: 379-385
31. McCrae RR The Cambridge Handbook of Personality Psychology. Corr PJ Matthews G, ed. Cambridge: Cambridge University Press ; 2009 :
32. McCrae RR, Costa PT. Personality trait structure as a human universal. Am Psychol. 1997 ; 52: 509-516 (Pubitemid 127458600)
33. McCrae RR, Herbst JH, Costa PT Personality and Temperament: Genetics, Evolution, and Structure. Riemann R Ostendorf F Spinath F, ed. Berlin: Pabst Science Publishers ; 2001: 217-231.
34. McGlothlin WH, Arnold DO. LSD revisited: a ten-year follow-up of medical LSD use. Arch Gen Psychiatry. 1971 ; 24: 35-49
35. McGlothlin WH, Cohen S, McGlothlin MS. Long lastingeffects of LSD on normals. Arch Gen Psychiatry. 1967 ; 17: 521-532
36. Metzner R, Editors . The subjective after-effects of psychedelic experiences: a summary of four recent questionnaire studies. Psychedel Rev. 1963 ; 1: 18-26
37. Miller WR. The phenomenon of quantum change. J Clin Psychol. 2004 ; 60: 453-460 (Pubitemid 38489994)
38. Mroczek DK, Spiro AI. Modeling intraindividual change in personality traits: Findings from the Normative Aging Study. J Gerontol B Psychol Sci Soc Sci. 2003 ; 58: 153-165
39. Nichols DE. Hallucinogens. Pharmacol Ther. 2004 ; 101: 131-181 (Pubitemid 38167565)
40. Pahnke WN (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis. Harvard University, Boston.
41. Paloutzian RF, Richardson JT, Rambo LR. Religious conversion and personality change. J Personal. 1999 ; 67: 1047-1079
42. Piedmont RL. Cracking the plaster cast: Big Five personality change during intensive outpatient counseling. J Res Personal. 2001 ; 35: 500-520
43. Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA. The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedel Drugs. 1977 ; 9: 1-10 (Pubitemid 8106580)
44. Roberts BW, Mroczek DK. Personality trait change in adulthood. Curr Dir Psychol Sci. 2008 ; 17: 31-35
45. Rosenberg DE, Isbell H, Miner EJ, Logan CR. The effect of N, N-Dimethyltryptamine in human subjects tolerant to lyseric acid diethylamide. Psychopharmacologia. 1964 ; 5: 217-227
46. Sahdra BK, MacLean KA, Shaver PR, et al. Enhanced response inhibition during intensive meditation training predicts improvements in self-reported adaptive socioemotional functioning. Emotion. 2011 ; 11: 299-312
47. Silvia PJ, Nusbaum EC, Berg C, Martin C, O'Connor A. Openness to experience, plasticity, and creativity: exploring lower-order, higher-order, and interactive effects. J Res Personal. 2009 ; 43: 1087-1090
48. Stace WT Mysticism and Philosophy. Philadelphia: Lipincott ; 1960 :
49. Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011 ; 25: 1434-1452
50. Terracciano A, McCrae RR, Brant LJ, Costa PT. Hierarchical linear modeling analyses of the NEO-PI-R scales in the Baltimore Longitudinal Study of Aging. Psychol Aging. 2005 ; 20: 493-506 (Pubitemid 41572553)
51. Terrill J, Savage C, Jackson DD LSD: The Consciousness-expanding Drug. Solomon D, ed. New York: G.P. Putnam's Sons ; 1964: 174-199.
52. Turek IS, Soskin RA, Kurland AA. Methylenedioxyamphetamine (MDA) subjective effects. J Psychedel Drugs. 1974 ; 6: 7-14
53. Unger SM LSD: The Consciousness-expanding Drug. Solomon D, ed. New York: G.P. Putnams Sons ; 1964: 200-228.
54. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010 ; 11: 642-651
55. Wolbach AB, Miner EJ, Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia. 1962 ; 3: 219-223